GlassScriptPhysician profile
Vernon S Chiu
NPI 1174705081
$2,634.56
in general payments reported to CMS, 2019-2025
27 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $62.42 · 2021: $398 · 2022: $408 · 2023: $334 · 2024: $588 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568 · Education: $44.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.91 |
| Education | $44.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $276.62 | 2019-2024 | Farxiga |
| Amgen INC. | $271.37 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Aurinia Pharma U.S., INC. | $227.11 | 2021-2024 | Lupkynis |
| Horizon Therapeutics Plc | $220.33 | 2020-2023 | Krystexxa |
| Travere Therapeutics, INC. | $191.11 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $174.02 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $154.03 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $146.13 | 2021-2025 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $135.57 | 2019-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $124.21 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $111.17 | 2024-2025 | |
| Ardelyx, INC. | $81.24 | 2025 | Ibsrela |
| Novo Nordisk INC | $75.76 | 2024-2025 | Ozempic, Wegovy, Rivfloza |
| Fresenius USA Marketing, INC. | $73.82 | 2019-2025 | Velphoro |
| Ani Pharmaceuticals, INC. | $52.43 | 2022-2025 | Purified Cortrophin Gel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.66 | 2024-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $39.05 | 2021-2023 | Ultomiris |
| Lilly USA, LLC | $34.12 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $32.06 | 2021 | |
| Akebia Therapeutics INC | $29.47 | 2021-2024 | Auryxia, Vafseo |
| Genzyme Corporation | $29.29 | 2019-2022 | |
| Cormedix INC. | $28.50 | 2024 | Defencath |
| Mallinckrodt Hospital Products INC. | $20.87 | 2025 | Acthar |
| Ultragenyx Pharmaceutical INC. | $16.26 | 2021 | |
| Opko Pharmaceuticals, LLC | $15.70 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.23 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vernon Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.